Ragifilimab is an agonistic humanized IgG1 kappa monoclonal antibody targeting glucocorticoid-induced TNFR-related protein (GITR, TNFRSF18). By binding and activating GITR, it stimulates T cell effector functions, enhances proliferation, and reduces the suppressive activity of regulatory T cells (Tregs) within the tumor microenvironment. It is being developed as an immunomodulatory therapy for advanced solid tumors, aiming to boost anti-tumor immunity.